Sfoglia per Autore
What therapies are on the horizon for HER2 positive breast cancer?
2019 G. Viale, S. Morganti, E. Ferraro, P. Zagami, A. Marra, G. Curigliano
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials
2020 C. Criscitiello, A. Marra, S. Morganti, P. Zagami, G. Viale, A. Esposito, G. Curigliano
Antibody-drug conjugates in breast cancer : the chemotherapy of the future?
2020 E. Nicolò, P. Zagami, G. Curigliano
Management of Cardiac Toxicity Induced by Chemotherapy
2020 D. Trapani, P. Zagami, E. Nicolò, G. Pravettoni, G. Curigliano
Systemic Treatment of Ductal Carcinoma In Situ of the Breast
2021 E. Crimini, C. Corti, M. Repetto, F. Giugliano, G. Antonarelli, P. Tarantino, P. Zagami, S. Morganti, E. Nicolo, J. Uliano, G. Curigliano
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
2021 F. Giugliano, E. Crimini, P. Tarantino, P. Zagami, J. Uliano, C. Corti, D. Trapani, G. Curigliano, P.A. Ascierto
Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature
2021 F. Conforti, P. Tarantino, P. Trillo, L. Pala, P. Zagami, S. Pirola, B. Di Venosa, C. Catania, P. Queirolo, E. Pennacchioli, P. Della Vigna, G. Curigliano, T.M. De Pas
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2
2021 A. Marra, D. Generali, P. Zagami, V. Cervoni, S. Gandini, S. Venturini, S. Morganti, R. Passerini, R. Orecchia, G. Curigliano
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis
2021 A. Esposito, A. Marra, V. Bagnardi, S. Frassoni, S. Morganti, G. Viale, P. Zagami, G.M. Varano, G. Buccimazza, F. Orsi, K. Venetis, L. Mazzarella, G. Viale, N. Fusco, C. Criscitiello, G. Curigliano
Characterization of low HER2 expressions in de-novo metastatic breast cancer
2021 P. Tarantino, E. Nicolo, P. Zagami, F. Giugliano, P. Aliaga, E. Crimini, C. Corti, J. Uliano, S. Morganti, L. Mazzarella, C. Criscitiello, A. Esposito, G. Curigliano
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials
2021 C. Criscitiello, A. Marra, S. Morganti, P. Zagami, S. Gandini, A. Esposito, G. Curigliano
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations
2021 E. Nicolò, D. Trapani, P.P.M. Berton Giachetti, P. Zagami, G. Curigliano
Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist
2022 P. Zagami, S. Morganti, P. Tarantino, G. Curigliano
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
2022 F. Conforti, P.A. Zucali, L. Pala, C. Catania, V. Bagnardi, I. Sala, P. Della Vigna, M. Perrino, P. Zagami, C. Corti, S. Stucchi, M. Barberis, E. Guerini-Rocco, B. Di Venosa, F. De Vincenzo, N. Cordua, A. Santoro, G. Giaccone, T.M. De Pas
Evolution of low HER2 expression between early and advanced-stage breast cancer
2022 P. Tarantino, S. Gandini, E. Nicolo, P. Trillo, F. Giugliano, P. Zagami, G. Vivanet, F. Bellerba, D. Trapani, A. Marra, A. Esposito, C. Criscitiello, G. Viale, G. Curigliano
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
2022 S. Morganti, A. Marra, E. Crimini, P. D'Amico, P. Zagami, G. Curigliano
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents
2022 P. Tarantino, O. D'Ecclesiis, E. Nicolò, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M.A. Locatelli, C. Belli, A. Esposito, I. Minchella, S.M. Tolaney, G. Curigliano
Triple negative breast cancer: Pitfalls and progress
2022 P. Zagami, L.A. Carey
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer
2022 S. Morganti, A. Marra, K. Venetis, E. Sajjadi, L. Ascione, C. Corti, P. Zagami, M. Ivanova, L. Zattoni, G. Curigliano, N. Fusco, C. Criscitiello
Metaplastic breast cancer: an all-round multidisciplinary consensus
2023 G. Corso, C. Criscitiello, L. Nicosia, F. Pesapane, E. Vicini, F. Magnoni, A. Sibilio, C. Zanzottera, A.M. De Scalzi, S. Mannucci, M. Marabelli, M. Calvello, I. Feroce, P. Zagami, F.M. Porta, A. Toesca, P. Tarantino, E. Nicolò, G. Mazzarol, C. La Vecchia, B. Bonanni, M.C. Leonardi, P. Veronesi, N. Fusco
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile